Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive159AccountSocial
MARKETSINVESTLIVE159
Product
Kalshi ProInvestMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Medicine

Will the FDA approve retatrutide?

Chance
Before Jul 1, 2027
20%
▲ 2

Before Jul 1, 2027

20%
▲ 2
Before Jan 1, 2028
56%

Before Jan 1, 2028

56%
Before Jul 1, 2028
85%

Before Jul 1, 2028

85%
2 more
Will the FDA approve retatrutide?

Before Jan 1, 2027

Odds
4% chance
Max payout
Dec 31, 2026
$0
$82,083 vol
More Science and Technology Markets

Trending Science and Technology markets

Best AI at the end of 2026?Will the U.S. confirm that aliens exist?How many launches will SpaceX have in November?When will OpenAI release Astra 6.1?When will Anthropic release Mythos?Where will Waymo operate this year?Open vs. Closed Token Volume (open weights share) in Nov 1, 2026Which AI will be the first to hit 1550 on Text Arena?

Science and Technology hub

All Science and Technology markets